Roberto A. Calle
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Roberto A. Calle has a total of 250 co-authors. Here are the top co-authors by number of shared publications:
- Clare Buckeridge
Pfizer Research and Development Cambridge Massachusetts USA
18 shared publications - Shannon L. Lubaczewski
Early Clinical Development Biomedicine Artificial Intelligence, Pfizer Inc, Collegeville, Pennsylvania
18 shared publications - Susie M. Collins
Global Biometrics and Data Management, Pfizer R&D UK Ltd, Sandwich, Kent, United Kingdom
18 shared publications - Anil Tarachandani
Early Clinical Development, Pfizer Inc, Cambridge, Massachusetts
17 shared publications - Ellen Q. Wang
Clinical Pharmacology & Bioanalytics, Pfizer Inc. New York New York USA
17 shared publications - James H. Revkin
Internal Medicine Research Unit, Pfizer Inc, Cambridge, Massachusetts
17 shared publications
Latest Publications
- 28 April 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (5) , 1567-1568
A reasonably likely surrogate endpoint for metabolic dysfunction–associated steatohepatitis
- 28 April 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (5) , 1567-1568
A reasonably likely surrogate endpoint for metabolic dysfunction–associated steatohepatitis
- 1 September 2024
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 312 (3) , e233094
Reproducibility and Repeatability of US Shear-Wave and Transient Elastography in Nonalcoholic Fatty Liver Disease
This prospective study defines expected US elastography measurement variability to guide clinical interpretation, enable diagnostic enrichment in clinical trials, and support U.S. Food and Drug Administration biomarker validation for nonalcoholic fatty liver disease.
- 1 September 2024
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 312 (3) , e233094
Reproducibility and Repeatability of US Shear-Wave and Transient Elastography in Nonalcoholic Fatty Liver Disease
This prospective study defines expected US elastography measurement variability to guide clinical interpretation, enable diagnostic enrichment in clinical trials, and support U.S. Food and Drug Administration biomarker validation for nonalcoholic fatty liver disease.
- Open Access
- 16 February 2024
- Published by Wiley in Clinical and Translational Science
- Vol. 17 (2) , e13687
Investigation of pharmacokinetic drug interaction between clesacostat and DGAT2 inhibitor ervogastat in healthy adult participants
Co‐administration of clesacostat (acetyl‐CoA carboxylase inhibitor, PF‐05221304) and ervogastat (diacylglycerol O‐acyltransferase inhibitor, PF‐06865571) in laboratory models improved non‐alcoholic fatty liver disease (NAFLD)/non‐alcoholic steatohepatitis (NASH) end points and mitigated clesacostat‐induced elevations in circulating triglycerides. Clesacostat is cleared via organic anion‐transporting polypeptide‐mediated hepatic uptake and cytochrome P450 family 3A (CYP3A); in vitro clesacostat is identified as a potential CYP3A time‐dependent inactivator. In vitro ervogastat is identified as a substrate and potential inducer of CYP3A. Prior to longer‐term efficacy trials in participants with NAFLD, safety and pharmacokinetics (PK) were evaluated in a phase I, non‐randomized, open‐label, fixed‐sequence trial in healthy participants. In Cohort 1, participants (n = 7) received clesacostat 15 mg twice daily (b.i.d.) alone (Days 1–7) and co‐administered with ervogastat 300 mg b.i.d. (Days 8–14). Mean systemic clesacostat exposures, when co‐administered with ervogastat, decreased by 12% and 19%, based on maximum plasma drug concentration and area under the plasma drug concentration–time curve during the dosing interval, respectively. In Cohort 2, participants (n = 9) received ervogastat 300 mg b.i.d. alone (Days 1–7) and co‐administered with clesacostat 15 mg b.i.d. (Days 8–14). There were no meaningful differences in systemic ervogastat exposures when administered alone or with clesacostat. Clesacostat 15 mg b.i.d. and ervogastat 300 mg b.i.d. co‐administration was overall safe and well tolerated in healthy participants. Cumulative safety and no clinically meaningful PK drug interactions observed in this study supported co‐administration of these two novel agents in additional studies exploring efficacy and safety in the management of NAFLD.
- 16 February 2024
- Published by Wiley in Clinical and Translational Science
- Vol. 17 (2) , e13687
Open AccessInvestigation of pharmacokinetic drug interaction between clesacostat and DGAT2 inhibitor ervogastat in healthy adult participants
Co‐administration of clesacostat (acetyl‐CoA carboxylase inhibitor, PF‐05221304) and ervogastat (diacylglycerol O‐acyltransferase inhibitor, PF‐06865571) in laboratory models improved non‐alcoholic fatty liver disease (NAFLD)/non‐alcoholic steatohepatitis (NASH) end points and mitigated clesacostat‐induced elevations in circulating triglycerides. Clesacostat is cleared via organic anion‐transporting polypeptide‐mediated hepatic uptake and cytochrome P450 family 3A (CYP3A); in vitro clesacostat is identified as a potential CYP3A time‐dependent inactivator. In vitro ervogastat is identified as a substrate and potential inducer of CYP3A. Prior to longer‐term efficacy trials in participants with NAFLD, safety and pharmacokinetics (PK) were evaluated in a phase I, non‐randomized, open‐label, fixed‐sequence trial in healthy participants. In Cohort 1, participants (n = 7) received clesacostat 15 mg twice daily (b.i.d.) alone (Days 1–7) and co‐administered with ervogastat 300 mg b.i.d. (Days 8–14). Mean systemic clesacostat exposures, when co‐administered with ervogastat, decreased by 12% and 19%, based on maximum plasma drug concentration and area under the plasma drug concentration–time curve during the dosing interval, respectively. In Cohort 2, participants (n = 9) received ervogastat 300 mg b.i.d. alone (Days 1–7) and co‐administered with clesacostat 15 mg b.i.d. (Days 8–14). There were no meaningful differences in systemic ervogastat exposures when administered alone or with clesacostat. Clesacostat 15 mg b.i.d. and ervogastat 300 mg b.i.d. co‐administration was overall safe and well tolerated in healthy participants. Cumulative safety and no clinically meaningful PK drug interactions observed in this study supported co‐administration of these two novel agents in additional studies exploring efficacy and safety in the management of NAFLD.
- Open Access
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from A Phase Ib First-In-Patient Study Assessing the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ponsegromab in Participants with Cancer and Cachexia
Summary of accelerometry-based monitoring of sedentary activity time (A), light activity time (B), moderate activity time (C), average activity level during the maximum 6 minutes of daily activity (D), total sleep time (E), and gait speed (F) at baseline, week 6 and week 12
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from A Phase Ib First-In-Patient Study Assessing the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ponsegromab in Participants with Cancer and Cachexia
Summary of accelerometry-based monitoring of sedentary activity time (A), light activity time (B), moderate activity time (C), average activity level during the maximum 6 minutes of daily activity (D), total sleep time (E), and gait speed (F) at baseline, week 6 and week 12
- Open Access
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from A Phase Ib First-In-Patient Study Assessing the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ponsegromab in Participants with Cancer and Cachexia
Representativeness of Study Participants
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from A Phase Ib First-In-Patient Study Assessing the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ponsegromab in Participants with Cancer and Cachexia
Representativeness of Study Participants
- Open Access
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Methods 1 from A Phase Ib First-In-Patient Study Assessing the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ponsegromab in Participants with Cancer and Cachexia
Summary of supplementary methods
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods 1 from A Phase Ib First-In-Patient Study Assessing the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ponsegromab in Participants with Cancer and Cachexia
Summary of supplementary methods
- Open Access
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Methods 1 from A Phase Ib First-In-Patient Study Assessing the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ponsegromab in Participants with Cancer and Cachexia
Summary of supplementary methods
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods 1 from A Phase Ib First-In-Patient Study Assessing the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ponsegromab in Participants with Cancer and Cachexia
Summary of supplementary methods
- Open Access
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from A Phase Ib First-In-Patient Study Assessing the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ponsegromab in Participants with Cancer and Cachexia
Summary of serum unbound and total ponsegromab Ctrough
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from A Phase Ib First-In-Patient Study Assessing the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ponsegromab in Participants with Cancer and Cachexia
Summary of serum unbound and total ponsegromab Ctrough